7.71
0.00%
+0.00
After Hours:
7.71
Burning Rock Biotech Ltd ADR stock is currently priced at $7.71, with a 24-hour trading volume of 10,314.
It has seen a +0.00% increased in the last 24 hours and a +863.75% rose in the past month.
The chart indicates a potential bullish trend, as the stock is below the $7.71 pivot point. If it approaches the $7.71 support level, significant changes may occur.
Previous Close:
$7.71
Open:
$7.49
24h Volume:
10,314
Market Cap:
$79.09M
Revenue:
$79.32M
Net Income/Loss:
$-100.37M
P/E Ratio:
-7.211
EPS:
-1.0692
Net Cash Flow:
$-44.34M
1W Performance:
-1.15%
1M Performance:
+863.75%
6M Performance:
+898.58%
1Y Performance:
+255.30%
Burning Rock Biotech Ltd ADR Stock (BNR) Company Profile
Name
Burning Rock Biotech Ltd ADR
Sector
Industry
Phone
86 20 3403 7871
Address
Building 3, Standard Industrial Unit 2, Room 601, 6th Floor No. 7, Luoxuan 4th Road International Bio Island, Guangzhou
Burning Rock Biotech Ltd ADR Stock (BNR) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Oct-15-21 | Resumed | Cowen | Outperform |
Jul-07-20 | Initiated | Cowen | Outperform |
Burning Rock Biotech Ltd ADR Stock (BNR) Latest News
LiveRamp (RAMP) Tops Q2 Earnings and Revenue Estimates - Yahoo New Zealand News
Yahoo New Zealand News
Burning Rock Regains Compliance with NASDAQ Minimum Bid Price Requirement
GlobeNewswire Inc.
Bayer and Burning Rock collaborate to increase patient access to precision cancer medicines
GlobeNewswire Inc.
Earnings call: Burning Rock returns to profitability in Q1 2024 By Investing.com - Investing.com Canada
Investing.com Canada
Earnings call: Burning Rock returns to profitability in Q1 2024 - Investing.com India
Investing.com India
Earnings call: Burning Rock returns to profitability in Q1 2024 By Investing.com - Investing.com
Investing.com
Burning Rock Biotech Ltd ADR Stock (BNR) Financials Data
Burning Rock Biotech Ltd ADR (BNR) Revenue 2024
BNR reported a revenue (TTM) of $79.32 million for the quarter ending September 30, 2023, a -8.53% decline year-over-year.
Burning Rock Biotech Ltd ADR (BNR) Net Income 2024
BNR net income (TTM) was -$100.37 million for the quarter ending September 30, 2023, a +34.75% increase year-over-year.
Burning Rock Biotech Ltd ADR (BNR) Cash Flow 2024
BNR recorded a free cash flow (TTM) of -$44.34 million for the quarter ending September 30, 2023, a +40.38% increase year-over-year.
Burning Rock Biotech Ltd ADR (BNR) Earnings per Share 2024
BNR earnings per share (TTM) was -$0.98 for the quarter ending September 30, 2023, a +33.43% growth year-over-year.
About Burning Rock Biotech Ltd ADR
Burning Rock Biotech develops solutions for precision medicine in oncology and early cancer detection in the People's Republic of China. The company provides companion diagnostics for targeted therapy and immunotherapy, benign/malignant tumor diagnosis, minimal residual disease monitoring, tumor recurrence and progression prediction, and tumor susceptibility tests. It also offers liquid biopsy; OncoScreen Plus, a test for therapy and immunotherapy; LungPlasma, a test for non-small cell lung cancer, including various genes that have a targeted therapy; ColonCore for testing gastrointestinal cancers; and HRDCore for testing genes associated with homologous recombination deficiency. Burning Rock Biotech was founded in 2014 and is headquartered in Guangzhou, China.
Cap:
|
Volume (24h):